EP3763735A1 - Procédé de préparation d'un biomatériau ayant une tyrosine fonctionnalisée de manière sélective, biomatériau ayant une tyrosine fonctionnalisée de manière sélective, et composition pharmaceutique le contenant en tant que principe actif - Google Patents

Procédé de préparation d'un biomatériau ayant une tyrosine fonctionnalisée de manière sélective, biomatériau ayant une tyrosine fonctionnalisée de manière sélective, et composition pharmaceutique le contenant en tant que principe actif Download PDF

Info

Publication number
EP3763735A1
EP3763735A1 EP19763931.3A EP19763931A EP3763735A1 EP 3763735 A1 EP3763735 A1 EP 3763735A1 EP 19763931 A EP19763931 A EP 19763931A EP 3763735 A1 EP3763735 A1 EP 3763735A1
Authority
EP
European Patent Office
Prior art keywords
biomaterial
formula
branched
straight
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19763931.3A
Other languages
German (de)
English (en)
Other versions
EP3763735A4 (fr
Inventor
Byeong Moon Kim
Yan Lee
Eun Joung Choi
Dongwook Jung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SNU R&DB Foundation
Original Assignee
Seoul National University R&DB Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seoul National University R&DB Foundation filed Critical Seoul National University R&DB Foundation
Publication of EP3763735A1 publication Critical patent/EP3763735A1/fr
Publication of EP3763735A4 publication Critical patent/EP3763735A4/fr
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21001—Chymotrypsin (3.4.21.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21004—Trypsin (3.4.21.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to a method for preparing a biomaterial having selectively functionalized tyrosine and a pharmaceutical composition containing the same as an active ingredient.
  • lysine (Lys)-succinamide and cysteine (Cys)-maleimide coupling reactions are widely used for functionalization of natural amino acids.
  • lysine (Lys)-succinamide coupling reaction most proteins have a large number of lysines on the surface, and thus non-selective reactions occur, resulting in the production of a mixture.
  • cysteine (Cys)-maleimide coupling reaction functionalization may occur when there is cysteine on the protein surface.
  • EPO erythropoietin
  • rhEPO recombinant human erythropoietin
  • PEG polyethylene glycol
  • PEG conjugation that is PEGylation
  • Mircera a PEGylated form of the rhEPO drug
  • the PEGylation of Mircera is based on Lys-succinimide chemistry, and it mostly reacts with Lys-45 or Lys-52 of the 7 lysine residues on the rhEPO surface, resulting in the production of a heterogeneous mixture of PEGylated rhEPO isomers, which makes purification difficult.
  • the present invention provides a protein in which a compound represented by formula 2 is bound to -OH group of tyrosine of the biomaterial containing tyrosine present on the surface in an aqueous solution: (In formula 2, A, L and B are as defined in formula 1 in a method for preparing a biomaterial to which a compound represented by formula 2 is coupled.).
  • the present invention provides a method for PEGylating a biomaterial comprising a step of reacting a compound represented by formula 1 and a biomaterial containing tyrosine present on the surface in an aqueous solution in the presence of a compound represented by formula 3: (In formula 1,
  • the method for preparing a biomaterial to which a compound represented by formula 2 is coupled allows the compound represented by formula 2 to be selectively coupled, in a high yield in a biomaterial, to tyrosine, which is present on the surface in an aqueous solution such that the coupling thereof to amino acids other than tyrosine does not occur and, when only one tyrosine is present, heterogeneous mixtures are not present and the inherent activity of the biomaterial is maintained, and thus the compound can be effectively used as a pharmaceutical composition containing a biomaterial drug as an active ingredient.
  • the method can selectively functionalize tyrosine, and thus can be effectively used for tyrosine functionalization in a biomaterial.
  • the present invention provides a method for preparing a biomaterial to which a compound represented by formula 2 is coupled comprising a step of reacting a compound represented by formula 1 and a biomaterial containing tyrosine present on the surface in an aqueous solution in the presence of a compound represented by formula 3. (In formula 1,
  • - OH of tyrosine and -F of the compound represented by formula 1 react in the presence of the compound in an aqueous solution.
  • the structure of A does not affect the reaction, and is not limited to a specific structure.
  • the B is a compound for imparting functionality to a biomaterial.
  • the compound may mean a biocompatible polymer.
  • the compound for imparting functionality to the biomaterial can be an organic or inorganic fluorescent substance.
  • the organic fluorescent substance can be rhodamine.
  • To impart functionality to the biomaterial means to impart specific functionality to the biomaterial (functionalization), such as functionalization of the biomaterial itself (e.g., PEGylation), attachment of antibodies or complements, and attachment of fluorescent substances, and B can be used without restrictions as long as it makes this possible.
  • alkoxy or hydroxypolyalkyleneoxide having a weight average molecular weight of 100 to 50000, wherein alkoxy can be straight or branched C 1-3 alkoxy, and alkylene can be straight or branched C 1-3 alkylene.
  • B can be methoxy polyethyleneoxide having a weight average molecular weight of 100 to 50000.
  • the peptide polymer can be a polymer randomly bound with one or more amino acids selected from the natural amino acid group consisting of valine, leucine, isoleucine, methionine, phenylalanine, asparagine, glutamic acid, aspartic acid, glycine, alanine, serine, threonine, cysteine, proline, glutamine, histidine, lysine, arginine, tyrosine and tryptophan.
  • the weight average molecular weight of B can be 100 to 50000.
  • the weight average molecular weight of B can be 500 to 40000.
  • the weight average molecular weight may vary depending on the weight average molecular weight of the B starting material used in the preparation of the compound represented by formula 1.
  • - OH of tyrosine and -F of the compound represented by formula 1 react in the presence of the compound in an aqueous solution.
  • the structure of B does not affect the reaction, and is not limited to a specific structure.
  • the compound represented by formula 3 when X is N, the compound represented by formula 3 may be a guanidine derivative.
  • R b , R c , R d and R e are independently hydrogen or straight or branched C 1-3 alkyl.
  • R a , R b , R c , R d and R e are independently hydrogen or methyl.
  • the compound represented by formula 3 may be an amidine derivative.
  • R a , R b , R c , R d and R e are independently hydrogen or methyl.
  • the compound represented by formula 3 can be DBU (1,8-Diazabicyclo(5.4.0)undec-7-ene) or TMG (1,1,3,3-tetramethylguanidine).
  • the preparation method of the present invention is characterized in that -OH of tyrosine and -F of the compound represented by formula 1 react in the presence of a compound represented by formula 3 in an aqueous solution.
  • a compound represented by formula 3 is required.
  • the reaction proceeds with an amine other than the compound represented by formula 3, the reaction may not proceed, or a problem may arise that the selectivity for tyrosine is lowered (see Experimental Example 1 and Table 1).
  • the tyrosine can be present in the hydrophilic region.
  • the biomaterial can be EPO (erythropoietin), chymotrypsinogen A, or activated chymotrypsin.
  • the polar solvent can be used for increasing the solubility of the compound represented by formula 1 when the biomaterial is reacted with the compound represented by formula 1.
  • the compound represented by formula 2 selectively binds only to the outer surface of rhEPO, that is, Tyr-49 present in an aqueous solution. In addition, none of the internal tyrosine residues bind to the compound (see Experimental Example 3 and Tables 3 and 4).
  • A can be phenylene, xanthine or coumarin.
  • the B is a compound for imparting functionality to a biomaterial.
  • the compound may mean a biocompatible polymer.
  • the compound for imparting functionality to the biomaterial can be an organic or inorganic fluorescent substance.
  • the organic fluorescent substance can be rhodamine.
  • To impart functionality to the biomaterial means to impart specific functionality to the biomaterial (functionalization), such as functionalization of the biomaterial itself (e.g., PEGylation), attachment of antibodies or complements, and attachment of fluorescent substances, and B can be used without restrictions as long as it makes this possible.
  • B can be methoxy polyethyleneoxide having a weight average molecular weight of 100 to 50000.
  • the peptide polymer can be a polymer randomly bound with one or more amino acids selected from the natural amino acid group consisting of valine, leucine, isoleucine, methionine, phenylalanine, asparagine, glutamic acid, aspartic acid, glycine, alanine, serine, threonine, cysteine, proline, glutamine, histidine, lysine, arginine, tyrosine and tryptophan.
  • the weight average molecular weight of B can be 100 to 50000.
  • the weight average molecular weight of B can be 500 to 40000.
  • the weight average molecular weight of B can be 1000 to 30000.
  • the protein is not limited as long as it is a biomaterial containing tyrosine present on the surface in an aqueous solution, but can be erythropoietin (EPO), chymotrypsinogen A, or activated chymotrypsin.
  • EPO erythropoietin
  • chymotrypsinogen A chymotrypsinogen A
  • activated chymotrypsin activated chymotrypsin.
  • the compound represented by formula 2 selectively binds only to the outer surface of rhEPO (recombinant human EPO (erythropoietin)), that is, Tyr-49 present in an aqueous solution. In addition, none of the internal tyrosine residues bind to the compound (see Experimental Example 3 and Tables 3 and 4).
  • the compound represented by formula 2 selectively binds only to Tyr-49 present in an aqueous solution, and thus which maintains the hematopoietic function, an inherent function of EPO (see Experimental Example 4 and Figure 6 ).
  • the protein to which the compound represented by formula 2 of the present invention is bound is selectively bound to tyrosine of the protein containing tyrosine present on the surface in an aqueous solution.
  • functionalization PEGylation in one embodiment of the present invention
  • selectively occurs only in the 49 th tyrosine of rhEPO, so there is no side effect of generating a heterogeneous mixture of Mircera, the conventional PEGylated rhEPO drug, and selective functionalization of the protein occurs with an excellent yield. Therefore, the product of the present invention can be effectively used as a selectively PEGylated protein drug.
  • the protein to which the compound represented by formula 2 is bound can be used as a pharmaceutical composition comprising the same as an active ingredient.
  • the present invention provides a method for PEGylating a biomaterial comprising a step of reacting a compound represented by formula 1 and a biomaterial containing tyrosine present on the surface in an aqueous solution in the presence of a compound represented by formula 3. (In formula 1,
  • A can be phenylene, xanthine or coumarin.
  • alkoxy or hydroxypolyalkyleneoxide having a weight average molecular weight of 100 to 50000, wherein alkoxy can be straight or branched C 1-3 alkoxy, and alkylene can be straight or branched C 1-3 alkylene.
  • B can be methoxy polyethyleneoxide having a weight average molecular weight of 100 to 50000.
  • the weight average molecular weight of B can be 500 to 40000.
  • the weight average molecular weight of B can be 1000 to 30000.
  • the weight average molecular weight may vary depending on the weight average molecular weight of the B starting material used in the preparation of the compound represented by formula 1.
  • the compound represented by formula 3 when X is N, the compound represented by formula 3 may be a guanidine derivative.
  • R b , R c , R d and R e are independently hydrogen or straight or branched C 1-3 alkyl.
  • R a , R b , R c , R d and R e are independently hydrogen or methyl.
  • R a , R b , R c , R d and R e are independently hydrogen or methyl.
  • the compound represented by formula 3 can be DBU (1,8-Diazabicyclo(5.4.0)undec-7-ene) or TMG (1,1,3,3-tetramethylguanidine).
  • the compound represented by formula 3 can be TMG (1,1,3,3-tetramethylguanidine).
  • the present invention provides a composition for hematopoiesis comprising EPO (erythropoietin), a biomaterial containing tyrosine present on the surface in an aqueous solution, to which a compound represented by formula 2 is bound to -OH group of the tyrosine as an active ingredient.
  • EPO erythropoietin
  • formula 2 a compound represented by formula 2 is bound to -OH group of the tyrosine as an active ingredient.
  • A can be phenylene, xanthine or coumarin.
  • the B is a compound for imparting functionality to a biomaterial.
  • the compound may mean a biocompatible polymer.
  • the compound for imparting functionality to the biomaterial can be an organic or inorganic fluorescent substance.
  • the organic fluorescent substance can be rhodamine.
  • To impart functionality to the biomaterial means to impart specific functionality to the biomaterial (functionalization), such as functionalization of the biomaterial itself (e.g., PEGylation), attachment of antibodies or complements, and attachment of fluorescent substances, and B can be used without restrictions as long as it makes this possible.
  • B is any one selected from the group consisting of alkoxy or hydroxypolyalkyleneoxide having a weight average molecular weight of 100 to 50000, poly(2-alkyl methacryloyloxyethyl phosphorylcholine) having a weight average molecular weight of 100 to 50000, poly(alkyl methacylate) having a weight average molecular weight of 100 to 50000, and peptide polymers having a weight average molecular weight of 100 to 50000, wherein alkoxy can be straight or branched C 1-5 alkoxy, alkylene can be straight or branched C 1-5 alkylene, and alkyl can be straight or branched C 1-5 alkyl.
  • B can be methoxy polyethyleneoxide having a weight average molecular weight of 100 to 50000.
  • the peptide polymer can be a polymer randomly bound with one or more amino acids selected from the natural amino acid group consisting of valine, leucine, isoleucine, methionine, phenylalanine, asparagine, glutamic acid, aspartic acid, glycine, alanine, serine, threonine, cysteine, proline, glutamine, histidine, lysine, arginine, tyrosine and tryptophan.
  • the weight average molecular weight of B can be 100 to 50000.
  • the weight average molecular weight of B can be 500 to 40000.
  • the weight average molecular weight may vary depending on the weight average molecular weight of the B starting material used in the preparation of the compound represented by formula 1.
  • the tyrosine can be 49 th tyrosine of EPO (erythropoietin).
  • the compound represented by formula 2 selectively binds only to Tyr-49 present in an aqueous solution, and thus which maintains the hematopoietic function, an inherent function of EPO (see Experimental Example 4 and Figure 6 ).
  • composition for hematopoiesis of the present invention comprising EPO to which a compound represented by formula 2 is bound as an active ingredient
  • functionalization PEGylation in one embodiment of the present invention
  • the composition of the present invention can be effectively used as a selectively PEGylated protein drug.
  • the composition for hematopoiesis can be used for the treatment or prevention of hematopoietic function-related diseases such as anemia, lymphocytic leukemia, myeloid leukemia, myeloma, idiopathic thrombocytopenic purpura, thrombocytopenia, hemophilia, von Willebrand disease, disseminated intravascular coagulation syndrome, nonspecific lymphadenitis, tuberculous lymphadenitis, sartoidosis, necrotizing lymphadenitis, Hodgkin lymphoma, non-Hodgkin lymphoma, splenomeglay and thymoma.
  • hematopoietic function-related diseases such as anemia, lymphocytic leukemia, myeloid leukemia, myeloma, idiopathic thrombocytopenic purpura, thrombocytopenia, hemophilia, von Willebrand disease, disseminated intravascular
  • the anemia can be caused by renal failure.
  • the anemia can be caused by a disease that requires regular peritoneal dialysis or hemodialysis.
  • composition for hematopoiesis can be used as a pharmaceutical composition for hematopoietic function-related diseases.
  • the pharmaceutical composition can be administered by parenterally and the parenteral administration includes subcutaneous injection, intravenous injection, intramuscular injection or intrathoracic injection.
  • the compound represented by formula 2 or the pharmaceutically acceptable salt thereof of the present invention is mixed with a stabilizer or a buffering agent to produce a solution or suspension, which is then formulated as ampoules or vials.
  • the composition herein can be sterilized and additionally contains preservatives, stabilizers, wettable powders or emulsifiers, salts and/or buffers for the regulation of osmotic pressure, and other therapeutically useful materials, and the composition can be formulated by the conventional mixing, granulating or coating method.
  • the formulations for oral administration are exemplified by tablets, pills, hard/soft capsules, solutions, suspensions, emulsions, syrups, granules, elixirs, and troches, etc.
  • These formulations can include diluents (for example, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, and/or glycine) and lubricants (for example, silica, talc, stearate and its magnesium or calcium salt, and/or polyethylene glycol) in addition to the active ingredient.
  • Tablets can include binding agents such as magnesium aluminum silicate, starch paste, gelatin, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrolidone, and if necessary disintegrating agents such as starch, agarose, alginic acid or its sodium salt or azeotropic mixtures and/or absorbents, coloring agents, flavours, and sweeteners can be additionally included thereto.
  • binding agents such as magnesium aluminum silicate, starch paste, gelatin, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrolidone
  • disintegrating agents such as starch, agarose, alginic acid or its sodium salt or azeotropic mixtures and/or absorbents, coloring agents, flavours, and sweeteners can be additionally included thereto.
  • the present invention provides a method for preventing or treating hematopoietic function-related diseases comprising a step of administering the composition for hematopoiesis comprising EPO (erythropoietin) containing tyrosine present on the surface in an aqueous solution to which a compound represented by formula 2 is bound to -OH group of the tyrosine as an active ingredient to a subject in need.
  • EPO erythropoietin
  • the present invention provides a use of the composition for hematopoiesis comprising EPO (erythropoietin) containing tyrosine present on the surface in an aqueous solution to which a compound represented by formula 2 is bound to -OH group of the tyrosine as an active ingredient for the treatment or prevention of hematopoietic function-related diseases.
  • EPO erythropoietin
  • Step 1 Preparation of methoxy polyethylene glycol tosylate
  • Step 3 Preparation of methoxy polyethylene glycol amine
  • Example 3 it was confirmed from the results of Example 3 that the preparation method according to the present invention was not limited to the EPO of Example 1. Particularly, the reaction occurred without being limited to any biomaterial containing tyrosine present on the surface in an aqueous solution. Not only PEGylation but also the introduction of a fluorescent substance was possible. Thus, it was found that the reaction could occur without limitation as long as it was a compound having a fosylate group and a biomaterial containing tyrosine present on the surface in an aqueous solution.
  • n (# of PEG) 15 16 17 18 19 20 21 22 23 24 Expected 1970 991 2015 018 2059 044 2103 07 2147 096 2191 122 2235 149 2279 175 2323 201 2367 227 Observed 1971 885 2015 838 2059 787 2103 762 2146 624 2191 638 2235 616 2279 585 2323 545 2367 508 n(#of PEG) 25 26 27 28 29 30 31 32 33 34 Expected 2411 254 2455 28 2499 306 2543 332 2587 358 2631 385 2675 411 2719 437 2763 463 2807 489 Observed 2411 456 2455 422 2499 375 2543 319 2587 292 2631 242 2675 204 2718 084 2763 122 2807 059 [Table 4] n (# of PEG) 18 19 20 21 22 23 24 Expected 1946.
  • the rhEPO without PEGylation and the PEGylated rhEPO (PEG-rhEPO) prepared in Example 1 were intravenously injected into Balb/c mice at a dose of 20 ⁇ g/kg every 3 days. In vivo activities were compared by measuring hematocrit (HCT), a reliable method for quantification of erythrocytes. As a control, phosphate buffered saline (PBS) was used.
  • HCT hematocrit
  • PBS phosphate buffered saline
  • rhEPO or PEG-rhEPO 0.0516 ⁇ M in DPBS
  • DPBS normal male Balb/c mice
  • a total of 21 mice were used in the experiment.
  • Blood samples were collected every 3 days including day 0 to evaluate the hematopoietic effect.
  • Hematocrit was evaluated by measuring the volume of the packed cells obtained by centrifugation performed immediately after the blood collection. Delta hematocrit (DHematocrit) was determined by the difference between the initial hematocrit for each mouse (day 0) and the hematocrit at each time point.
  • DHematocrit Delta hematocrit
  • HeLa cells were seeded in a 96-well tissue culture plate at the density of 5,000 cells/well and cultured in 100 ⁇ L of DMEM (Dulbecco's Modified Eagle's Medium) supplemented with 10% FBS (fetal bovine serum) for 24 hours. After replacing the medium with 90 ⁇ L of a fresh medium, 10 ⁇ l of the compound prepared in Preparative Example 4 of various concentrations (final 0.5% DMSO) was added to each well of the plate, and the cells were further cultured for 24 hours and 48 hours. The cells were washed 3 times with a fresh medium to remove extracellular samples, and 100 ⁇ l of a fresh medium containing 10% CCK-8 was added to each well of the plate.
  • DMEM Dynamic Eagle's Medium
  • FBS fetal bovine serum

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
EP19763931.3A 2018-03-06 2019-03-05 Procédé de préparation d'un biomatériau ayant une tyrosine fonctionnalisée de manière sélective, biomatériau ayant une tyrosine fonctionnalisée de manière sélective, et composition pharmaceutique le contenant en tant que principe actif Pending EP3763735A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180026582A KR102062848B1 (ko) 2018-03-06 2018-03-06 선택적으로 기능화된 타이로신을 가지는 생체 물질의 제조방법, 선택적으로 기능화된 타이로신을 가지는 생체 물질 및 이를 유효성분으로 함유하는 약학적 조성물
PCT/KR2019/002512 WO2019172605A1 (fr) 2018-03-06 2019-03-05 Procédé de préparation d'un biomatériau ayant une tyrosine fonctionnalisée de manière sélective, biomatériau ayant une tyrosine fonctionnalisée de manière sélective, et composition pharmaceutique le contenant en tant que principe actif

Publications (2)

Publication Number Publication Date
EP3763735A1 true EP3763735A1 (fr) 2021-01-13
EP3763735A4 EP3763735A4 (fr) 2021-06-09

Family

ID=67846645

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19763931.3A Pending EP3763735A4 (fr) 2018-03-06 2019-03-05 Procédé de préparation d'un biomatériau ayant une tyrosine fonctionnalisée de manière sélective, biomatériau ayant une tyrosine fonctionnalisée de manière sélective, et composition pharmaceutique le contenant en tant que principe actif

Country Status (4)

Country Link
US (1) US20210054038A1 (fr)
EP (1) EP3763735A4 (fr)
KR (1) KR102062848B1 (fr)
WO (1) WO2019172605A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022232377A2 (fr) * 2021-04-28 2022-11-03 The Regents Of The University Of California Protéines bioréactives contenant des acides aminés non naturels
WO2023236778A1 (fr) * 2022-06-10 2023-12-14 北京大学 Composé trifonctionnel et son utilisation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04000564A (es) 2001-07-20 2005-02-17 Univ Zuerich Composiciones y metodos para uso de agentes bioactivos derivados de aminoacidos sulfatados y sulfonados.
US20090252703A1 (en) * 2006-10-19 2009-10-08 Gegg Jr Colin V Use of alcohol co-solvents to improve pegylation reaction yields
US9447243B2 (en) * 2012-12-03 2016-09-20 The Scripps Research Institute Polymerization method and polymers formed therewith
EP4295841A3 (fr) * 2014-06-06 2024-03-13 The Scripps Research Institute Composés de fluorure de soufre (vi) et leurs utilisation dans les réactions click
CN114159552A (zh) 2015-01-09 2022-03-11 格纳西尼有限公司 使用长效epo配制物治疗贫血的方法

Also Published As

Publication number Publication date
EP3763735A4 (fr) 2021-06-09
US20210054038A1 (en) 2021-02-25
KR102062848B1 (ko) 2020-01-06
KR20190105897A (ko) 2019-09-18
WO2019172605A1 (fr) 2019-09-12

Similar Documents

Publication Publication Date Title
EP1857462B1 (fr) Derive de polyoxyalkylene
JP4698579B2 (ja) 可逆的ｐｅｇ化薬物
KR101128320B1 (ko) 아미도카르보네이트 연결기를 갖는 ｐｅｇ 유도체
US9649363B2 (en) Polyethylene glycol based prodrug of adrenomedullin and use thereof
US7407982B2 (en) Oligo or polyalkylene glycol-coupled thrombin inhibitors
JP7303640B2 (ja) Ｔｆｐｉ阻害剤および使用方法
BRPI0607248A2 (pt) conjugado de um polipeptìdeo e um oligossacarìdeo, composição farmacêutica, uso do conjugado, e, processo para a preparação de um conjugado
JP6051223B2 (ja) ペプチドの放出可能な結合のためのチロシンに基づくリンカー
MX2007016314A (es) Conjugados que tienen un enlace degradable y reactivos polimericos utiles en la preparacion de tales conjugados.
JP2006516277A (ja) 血漿カリクレインを阻害するためのアシル化４−アミジノ−または４−グアニジノベンジルアミン
EP3763735A1 (fr) Procédé de préparation d'un biomatériau ayant une tyrosine fonctionnalisée de manière sélective, biomatériau ayant une tyrosine fonctionnalisée de manière sélective, et composition pharmaceutique le contenant en tant que principe actif
ES2529258T3 (es) Métodos para preparar reactivos poliméricos
KR20070098934A (ko) 비히클에 아미노티올 함유 분자를 콘쥬게이션시키는방법
JP7411189B2 (ja) 分岐型分解性ポリエチレングリコール結合体
Steinmetzer et al. Beyond Heparinization: Design of highly potent thrombin inhibitors suitable for surface coupling
Bielmann et al. Synthesis of different glutathione–sulfur mustard adducts of verified and potential biomarkers
KR20220069994A (ko) 비대칭 분기형 분해성 폴리에틸렌글리콜 유도체
US20220296726A1 (en) Bicyclic peptide ligands specific for trem2
EP4355371A1 (fr) Réactifs polymères sélectifs à l'histidine
WO2005085283A1 (fr) Interleukine-11 modifiée et composition thérapeutique contenant celle-ci
NZ714621B2 (en) Polyethylene glycol based prodrug of adrenomedullin and use thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201006

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

A4 Supplementary search report drawn up and despatched

Effective date: 20210512

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/505 20060101AFI20210506BHEP

Ipc: C07K 19/00 20060101ALI20210506BHEP

Ipc: C12N 9/76 20060101ALI20210506BHEP

Ipc: A61K 47/60 20170101ALI20210506BHEP

Ipc: A61K 38/00 20060101ALI20210506BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230302